Prodrugs of a CDK inhibitor for treating cancers
US11225497B2 · kind B2 · utility
1Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 23, 2020 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Apr 23, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.